Mitogen-activated protein kinase kinase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
For other uses, see MKK (disambiguation).
Mitogen-activated protein kinase kinase
Identifiers
EC number 2.7.12.2
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum

Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

MAP2K is classified as EC 2.7.12.2.

There are seven genes:

The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase.

Role in Melanoma[edit]

MEK is a member of the MAPK signaling cascade that is activated in melanoma.[2] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

See also[edit]

References[edit]

  1. ^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science 267 (5198): 682–5. doi:10.1126/science.7839144. PMID 7839144. 
  2. ^ Falchook, Gerald S, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Douglas J DeMarini, and Leslie A Fecher, et al. 2012. "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial." The Lancet Oncology 13, no. 8: 782-789.

External links[edit]